Background: The optimal treatment for locally advanced esophageal squamous cell carcinoma remains unclear. We compared the clinical outcomes of neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy [the surgery group] and CCRT without surgery [the CCRT group] in patients with squamous cell carcinoma from an Asian population.

Methods: Eligible patients diagnosed from 2008 to 2015 were identified through the Taiwan Cancer Registry. To balance observable potential confounders, we constructed a 1:1 propensity score-matched cohort [surgery vs CCRT]. We compared the hazard ratios between the surgery and CCRT groups for death using a robust variance estimator. We also evaluated the outcomes of patients for freedom from local regional recurrence (FFLRR) and esophageal cancer-specific survival (ECSS). Extensive supplementary analyses were performed to examine the robustness of our findings.

Results: Our study population included 298 patients balanced with respect to the observed covariables. The hazard ratio of death was 0.56 [95% confidence interval 0.42~0.75] when surgery was compared to CCRT. The results remained significant in the FFLRR and ECSS outcomes. In the supplementary analyses, our results also remained significant when additional covariables were taken into consideration or when the definition of the index date was changed.

Conclusions: When compared to definitive CCRT, neoadjuvant CCRT followed by esophagectomy was associated with improved overall survival for locally advanced esophageal squamous cell carcinoma. However, given the nonrandomized nature of the study and the sensitivity to potentially unmeasured confounders, our results should be interpreted cautiously.

Keywords: Esophageal squamous cell carcinoma, Concurrent chemoradiotherapy, Esophagectomy
controlled trial (RCT) reported favorable outcomes when neoadjuvant CCRT followed by esophagectomy was compared to esophagectomy alone [4, 5]. In addition, RCTs for esophageal SqCC patients from Germany and France had reported similar overall survival (OS), although better local control was obtained with neoadjuvant CCRT followed by esophagectomy compared to CCRT without surgery (also mentioned in the 2017 review paper above) [3, 6, 7]. Another RCT also reported similar OS between CCRT without surgery and upfront esophagectomy without neoadjuvant CCRT [8].

Therefore, the aim of our study was to compare neoadjuvant CCRT followed by esophagectomy to definitive CCRT for locally advanced esophageal SqCC patients in a real-world Asian population.

Methods
Data source
In our study, the primary data comes from the Taiwan Cancer Registry (TCR) and death registration. The TCR is a high-quality database [9] that provides complete information such as individual demographics, stage of disease, tumor histology, and treatment details. Some prognostic factors, e.g., the use of positron emission tomography (PET), were also available since 2011.

Study population and study design
Our study flow chart, designed to conform to the STROBE guidelines [10], is depicted in Fig. 1. The main study population consisted of locally advanced esophageal SqCC patients diagnosed from 2008 to 2015 who received neoadjuvant CCRT [radiotherapy dose 40–50.4 Gy] before esophagectomy, or CCRT [radiotherapy dose ≥ 50.4 Gy] without surgery. The explanatory variable of interest in this study was the surgery group (neoadjuvant CCRT followed by esophagectomy) vs the CCRT group (CCRT without surgery). We collected covariates based on our experiences in clinical care and related TCR studies [11–13] for adjustment of potential nonrandomized treatment selection (as mentioned in the next section). We defined the date of diagnosis from the cancer registry as the index date and obtained the survival statuses of patients from the death registry [follow-up until Dec 31, 2016]. We then estimated propensity scores (PSs) using the covariates to construct a PS-matched sample. We used this PS-based method rather than a Cox regression model, as suggested in previous literature [14, 15].

![Fig. 1 STROBE study flow chart and the numbers of individuals at each stage of the study. 1: We only included those treated (classes 1–2) by any single institution to ensure data consistency. 2: Cancer staging clinical stage T3N1M0. 3: Without missing information in the TCR and the death registry](image)
Other explanatory covariables
Patient demographics [age, gender, residency region], disease characteristics [tumor size, differentiation, tumor location], radiotherapy (RT) delivery, institution, and period were included in our primary analysis. We also considered a prognostic factor ["use of PET", available in the TCR since 2011] in the supplementary analyses. The definitions of covariables were as follows. Patient residency region was classified as northern Taiwan or elsewhere. Tumor size was classified by a diameter ≤5 or > 5 cm. Tumor differentiation was classified as well/moderately differentiated or poorly/undifferentiated. External beam radiotherapy delivery was classified as image-guided radiotherapy (IGRT) or non-IGRT. The hospital was classified as a high- or low-volume institute via a threshold [20 esophagectomies per year] [16]. The time period was classified as 2008–2009 or 2010–2015. Tumor location was classified as cervical or not.

Statistical analysis
We performed the statistical analysis using the software SAS 9.4 (SAS Institute, Cary, NC, USA) and STATA 12 (StataCorp LP, College Station, TX, USA). In the primary analysis, we used a logistic regression model based on covariables to evaluate the probability of receiving surgery (vs CCRT) and then used the logit of the probability as the PS in a PS-matched method. Tabulation and standardized difference [17, 18] were used to assess the balance of covariates between PS-matched groups. We used a robust variance estimator to compare the hazard ratios of events between surgery- and CCRT-matched groups during the entire follow-up period [14]. As suggested in the recent literature [19], we evaluated the robustness of our findings to potential unmeasured confounding factor(s) via the E-factor. We also evaluated the outcomes of patients for freedom from local regional recurrence (FFLRR) and esophageal cancer-specific survival (ECSS) according to the TCR and the death registry.

Supplementary analyses
In a subgroup of patients [diagnosed from 2011 to 2015] for whom additional information, i.e., use of PET, was available, we performed the first supplementary analysis (SA-1). In the second supplementary analysis (SA-2), we repeated what we did in SA-1 but limited the surgery group to those who received minimally invasive esophagectomy (MIE) because of its potential superiority [20, 21]. In the third supplementary analysis (SA-3), we reanalyzed the OS in the primary analysis when the index date was changed to the start of radiotherapy.

Results
Identification of the study population used in the primary analysis
As shown in Fig. 1, the identified initial study population consisted of 451 esophageal SqCC cancer patients divided into surgery or CCRT groups. After excluding the missing data in follow-up and applying a PS matching method, 298 patients were used as the final study population in the primary analysis. The patient characteristics are described in Table 1. All covariables after matching were well balanced with small standardized differences (<0.25) [17].

Primary analysis
After a median follow-up of 20 months [range 3–98], death was observed for 79 patients in the surgery group and for 108 in the CCRT group. The hazard ratio (HR) of death when surgery was compared to CCRT was 0.56 [95% confidence interval (95CI) 0.42–0.75, \(p\) value < 0.001]. The observed HR 0.56 for OS could be explained by an unmeasured confounder associated with the selection of treatment (IMRT or 3DCRT) and live/death by a risk ratio of 2.35-fold each; however, weaker confounding factors could not do so. Furthermore, the confidence interval could be moved to include the null hypothesis by an unmeasured confounder by a risk ratio of 1.74, above and beyond the measured confounders; however, weaker confounding could not. The 5-year OS rate for surgery was 38% (vs 20% for CCRT). Figure 2 shows the Kaplan-Meier survival curve for OS. Surgery was also associated with better FFLRR [HR 0.17, 95CI 0.11–0.28, \(p\) value < .001] and ECSS [HR 0.56, 95CI 0.41–0.77, \(p\) value < 0.001].

Supplementary analyses
In the SA-1, which incorporated the use of PET into the PS model, all of the covariables were well balanced and the standardized differences were small (<0.25) (Table 2). From this analysis, we found that surgery was still associated with improved OS compared to CCRT [HR 0.51, 95CI 0.36–0.72, \(p\) value < 0.001]. Figure 3 shows the Kaplan-Meier survival curve for OS.

In the SA-2, in which neoadjuvant CCRT followed by MIE was compared to CCRT without surgery, all of the covariables were still well balanced with small standardized differences (<0.25) (Table 3). The HR of death when surgery [MIE] was compared to CCRT was 0.44 [95CI 0.28–0.70, \(p\) value < 0.001]. Figure 4 shows the Kaplan-Meier survival curve for OS.

In the SA-3 in which we used the RT-start date as the index date, the HR for death when surgery was compared with CCRT was similar [0.55, 95CI 0.41–0.74, \(p\) value < 0.001]. The Kaplan-Meier survival curves for OS are shown in Fig. 5.

Discussion
In this population-based study PS-matched analysis from Asia (Taiwan), we found that for locally advanced esophageal SqCC, neoadjuvant CCRT followed by esophagectomy was associated with improved OS when compared to CCRT without surgery.
### Table 1 Characteristics of matched study population in the primary analysis

|                      | Surgery       | Number or mean (sd)a  | (%)a  | CCRT       | Number or mean (sd)a  | (%)a  | Standardized differencea |
|----------------------|---------------|-----------------------|-------|------------|-----------------------|-------|--------------------------|
| **Age**              |               | 56.93 (8.65)          |       | 57.26 (10.48) |                       |       | 0.04                     |
| **Gender**           |               |                       |       |             |                       |       |                          |
| Female               | 8             | (5)                   |       | 7           | (5)                   |       | 0.03                     |
| Male                 | 141           | (95)                  |       | 142         | (95)                  |       |                          |
| **Residency**        |               |                       |       |             |                       |       |                          |
| Non-north            | 101           | (68)                  |       | 100         | (67)                  |       | 0.01                     |
| North                | 48            | (32)                  |       | 49          | (33)                  |       |                          |
| **Tumor size**       |               |                       |       |             |                       |       |                          |
| ≤ 5 cm               | 59            | (40)                  |       | 60          | (40)                  |       | 0.01                     |
| > 5 cm               | 90            | (60)                  |       | 89          | (60)                  |       |                          |
| **Differentiation**  |               |                       |       |             |                       |       |                          |
| Poorly/undifferentiated | 46       | (31)                  |       | 53          | (36)                  |       | 0.10                     |
| Well/moderately      | 103           | (69)                  |       | 96          | (64)                  |       |                          |
| **RT delivery**      |               |                       |       |             |                       |       |                          |
| Non-IGRT             | 131           | (88)                  |       | 128         | (86)                  |       | 0.06                     |
| IGRT                 | 18            | (12)                  |       | 21          | (14)                  |       |                          |
| **Institution**      |               |                       |       |             |                       |       |                          |
| Low volume           | 50            | (34)                  |       | 54          | (36)                  |       | 0.06                     |
| High volume          | 99            | (66)                  |       | 95          | (64)                  |       |                          |
| **Period**           |               |                       |       |             |                       |       |                          |
| 2008–2009            | 18            | (12)                  |       | 19          | (13)                  |       | 0.02                     |
| 2010–2015            | 131           | (88)                  |       | 130         | (87)                  |       |                          |
| **Location**         |               |                       |       |             |                       |       |                          |
| Cervical             | 1             | (1)                   |       | 1           | (1)                   |       | 0.00                     |
| Noncervical          | 148           | (99)                  |       | 148         | (99)                  |       |                          |

sd standard deviation, RT radiotherapy, IGRT image-guided RT, CCRT concurrent chemoradiotherapy

*Rounded*
Table 2 Characteristics of the matched study population in the SA-1

|                | Surgery Number or mean (sd)\(^a\) | CCRT Number or mean (sd)\(^a\) | Standardized difference\(^a\) |
|----------------|-----------------------------------|---------------------------------|------------------------------|
| Age            | 57.00 (7.63)                      | 56.61 (9.62)                    | 0.05                         |
| Gender         | Female 6 (5)                      | 3 (3)                           | 0.14                         |
|                | Male 104 (95)                     | 107 (97)                        |                              |
| Residency      | Non-north 76 (69)                 | 80 (73)                         | 0.08                         |
|                | North 34 (31)                     | 30 (27)                         |                              |
| Tumor size     | ≤ 5 cm 43 (39)                    | 42 (38)                         | 0.02                         |
|                | > 5 cm 67 (61)                    | 68 (62)                         |                              |
| Differentiation| Poorly/undifferentiated 41 (37)  | 42 (38)                         | 0.02                         |
|                | Well/moderately 69 (63)           | 68 (62)                         |                              |
| RT delivery    | Non-IGRT 94 (85)                  | 96 (87)                         | 0.05                         |
|                | IGRT 16 (15)                      | 14 (13)                         |                              |
| Institution    | Low volume 40 (36)                | 45 (41)                         | 0.09                         |
|                | High volume 70 (64)               | 65 (59)                         |                              |
| Use of PET     | Without 12 (11)                   | 12 (11)                         | 0.00                         |
|                | With 98 (89)                      | 98 (89)                         |                              |
| Location       | Cervical 1 (1)                    | 1 (1)                           | 0.00                         |
|                | Noncervical 109 (99)              | 109 (99)                        |                              |

sd standard deviation, RT radiotherapy, IGRT image-guided RT, PET positron emission tomography, CCRT concurrent chemoradiotherapy
\(^a\)Rounded

Fig. 3 Kaplan-Meier survival curve (in years) for a PS-matched subgroup diagnosed from 2011 to 2015 [SA-1]
### Table 3: Characteristics of the matched study population in the SA-2

| Characteristic                  | Surgery [MIE] | CCRT | Standardized difference<sup>a</sup> |
|--------------------------------|---------------|------|-------------------------------------|
|                                | Number or mean (sd)<sup>a</sup> | Number or mean (sd)<sup>a</sup> |                                     |
| Age                            | 56.38 (8.21)  | 55.35 (10.58) | 0.11                                |
| Gender                         | Female 4 (5)  | 4 (5) | 0.00                                |
|                                | Male 78 (95)  | 78 (95) |                                      |
| Residency                      | Non-north 57 (70) | 52 (63) | 0.13                                |
|                                | North 25 (30) | 30 (37) |                                      |
| Tumor size                     | ≤ 5 cm 31 (38) | 31 (38) | 0.00                                |
|                                | > 5 cm 51 (62) | 51 (62) |                                      |
| Differentiation                | Poorly/undifferentiated 31 (38) | 30 (37) | 0.03                                |
|                                | Well/moderately 51 (62) | 52 (63) |                                      |
| RT delivery                    | Non-IGRT 70 (85) | 68 (83) | 0.07                                |
|                                | IGRT 12 (15) | 14 (17) |                                      |
| Institution                    | Low volume 23 (28) | 25 (30) | 0.05                                |
|                                | High volume 59 (72) | 57 (70) |                                      |
| Use of PET                     | Without 7 (9) | 11 (13) | 0.16                                |
|                                | With 75 (91) | 71 (87) |                                      |

The nonoverlapped covariable (location) was not included in this matching.

<sup>a</sup>sd: standard deviation, RT: radiotherapy, IGRT: image-guided RT, PET: positron emission tomography, MIE: minimally invasive esophagectomy, CCRT: concurrent chemoradiotherapy.

<sup>a</sup>Rounded
Statistically, our results were not consistent with available RCTs [6, 7]; however, survival was actually numerically better for the surgical arm when compared to that for the nonsurgical arms in both RCTs, although not statistically significant. The 2-year OS was 39.9 vs 35.4% in the German trial [7] and 37.1 vs 36.5% [per protocol] in the French trial [6]. In our study, it was 63 vs 39%. Therefore, the outcome of CCRT in our study was similar to both RCTs, but the outcome of neoadjuvant CCRT followed by esophagectomy was higher in our study [63%] (although close to the 67% OS reported in the modern CROSS study [5]).

We feel that our findings are compatible with the prevalent concept that esophagectomy is an integral part of treatment for locally advanced esophageal cancer [1], possibly through improved disease control (demonstrated by the improved FFLRR and ECSS), as better local/regional control in the surgical arm had also been reported in the above RCTs [6, 7]. However, given the abovementioned RCTs and that our result was sensitive to potential unmeasured confounders [E-factor 1.74], we feel that our results should not be interpreted as conclusive and that further modern RCTs are needed.

There were some limitations in our study. First, we shared the inherent limitation of observation study. Although we tried our best to follow the STROBE guidelines for observational study [10] and examined extensive supplementary analyses, potential unmeasured confounder(s), such as presenting body weight loss [6] or operability, might still threaten our results. Second, the generalizability of our finding to regions where SqCC was not the predominant histology might be questionable.

**Conclusions**

We found that for locally advanced esophageal SqCC, neoadjuvant CCRT followed by esophagectomy was associated with improved OS when compared to CCRT without surgery. However, given the nonrandomized nature of the study and sensitivity to potential unmeasured confounder(s), our results should be interpreted cautiously.
Abbreviations
CCRT: Concurrent chemoradiotherapy; ECSS: Esophageal cancer-specific survival; FFLR: Freedom from local regional recurrence; IGRT: Image-guided radiotherapy; MIE: Minimally invasive esophagectomy; OS: Overall survival; PET: Positron emission tomography; PS: Propensity score; RCT: Randomized controlled trial; RT: Radiotherapy; SA: Supplementary analysis; SqCC: Squamous cell carcinoma; TCR: Taiwan Cancer Registry

Acknowledgements
The authors are thankful for the conceptual input from Dr. Tsang-Wu Liu and all of the members in the Health Promotion Administration, National Health Research Institute Esophageal Cancer Committee for their conceptual contributions. The authors thank “American Journal Experts” for editorial assistance. The corresponding author would like to thank Dr. Ya-Chen Tina Shih for her mentoring in Health Services Research.

Funding
This work was supported by the Health Promotion Administration, Ministry of Health and Welfare, Taiwan (R.O.C.) [source of this funding is the health and welfare surcharge of tobacco products] and China Medical University Hospital [CRS-106-040 to Chen C.R.]

Availability of data and materials
The data that support the findings of this study are available from the Taiwan Cancer Registry; however, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the Taiwan Cancer Registry.

Authors’ contributions
CYC participated in the conceptualization and design of the study, interpreted data, and drafted the manuscript. CCL participated in the conceptualization and design of study, analyzed data, and drafted the manuscript. CRC participated in the conceptualization and design of study, collected the related studies, analyzed and interpreted data, and drafted the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by Research Ethics Committee, National Health Ethics approval and consent to participate collected the related studies, analyzed and interpreted data, and drafted the conceptualization and design of study, analyzed data, and drafted the manuscript. CRC participated in the conceptualization and design of the study, analyzed data, and drafted the manuscript. CRC participated in the conceptualization and design of study, collected the related studies, analyzed and interpreted data, and drafted the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by Research Ethics Committee, National Health Research Institutes [EC1041006-E].

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University, Chung Shan Medical University Hospital, Taichung, Taiwan. 2Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan. 3Department of Radiation Oncology, China Medical University Hsin Chu Hospital, Hsinchu, Taiwan. 4School of Medicine, College of Medicine, China Medical University, No.91 Hsueh-Shih Road, North District, Taichung 40402, Taiwan.

Received: 23 January 2018 Accepted: 5 July 2018

References
1. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:
2499–509.
2. National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines for esophageal and esophagogastric junction cancers, version 3.2017 [free registration required]. https://www.nccn.org/ professionals/physician_gls/pdf/esophageal.pdf. Accessed 30 Sep 2017.
3. Chun SG, Skinner HD, Minsky BD. Radiation therapy for locally advanced esophageal cancer. Surg Oncol Clin N Am. 2017;26:257–76.
4. Špoustat KM, Borumseme BH, Smithers BM, Zalberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:e81–92.
5. Shapiro J, van Lanschot JJB, Hulshof MCM, van Hagen P, van Berge Henegouwen M, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
6. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.
7. Staud M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seebier S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.
8. Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. 2005;9:794–802.
9. Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45:291–6.
10. von Elm E, Altman DG, von Hagen P, van Hagen P, van Berge Henegouwen M, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
11. Chen CY, Li CC, Chen CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016;120:136–9.
12. Li CC, Chen CY, Chen CR. Comparative effectiveness of image-guided radiotherapy for non-operated localized esophageal squamous cell carcinoma patients receiving concurrent chemoradiotherapy: a population-based propensity score matched analysis. Oncotarget. 2016;7:71548–55.
13. Fang HY, Chen CY, Wang YC, Wang PH, Shieh SH, Chien CR. Consistently lower narcotics consumption after video-assisted thoracoscopic surgery for early stage non-small cell lung cancer when compared to open surgery: one-year follow-up study. Eur J Cardiothorac Surg. 2013;43:783–6.
14. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomised experiments. Stat Med. 2014;33:1242–58.
15. Jagi R, Bekelman JE, Chen A, Chen RC, Hoffman K, Shih YC, et al. Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys. 2014;90:11–24.
16. Gockel I, Ahlbrand CJ, Arras M, Schreiber EM, Lang H. Quality management and key performance indicators in oncolgic esophageal surgery. Dig Dis Sci. 2015;60:3536–44.
17. Garnido MM, Kelelsey AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701–20.
18. Ali MS, Groenvold RH, Belltsver SV, Pestman WR, Hoes AW, Roess KC, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal in a systematic review. J Clin Epidemiol. 2015;68:112–21.
19. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268–74.
20. Yibulayin W, Abulizi S, Lv H, Sun W. Minimally invasive esophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis. World J Surg Oncol. 2016;14:304.
21. Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, Bonavina L, et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann Surg. 2017;266:232–6.